Original Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2013; 19(14): 2154-2161
Published online Apr 14, 2013. doi: 10.3748/wjg.v19.i14.2154
Table 2 Treatment received by the patients with gastric cancer (n = 796) n (%)
Treatment
Adjuvant therapy5-FU-LV222 (27.9)
5-FU-LV/cisplatin43 (5.4)
Untreated follow-up58 (7.3)
Others17 (2.1)
Metastatic series 15-FU-LV32 (4)
DCF152 (19.1)
ECF77 (9.7)
5-FU-LV/cisplatin121 (15.2)
Palliative treatment112 (14.1)
Cisplatin/capecitabine20 (2.5)
Others31 (3.9)
Metastatic series 2DCF31 (3.9)
5-FU-LV/cisplatin19 (2.4)
ECF14 (2.3)
Irinotecan/cisplatin17 (2.1)
Supportive267 (33.5)
Others32 (4)